Comparative Study of Ethinyl Estradiol and Dienogest with Ethinyl Estradiol and Levonorgestrel in the Management of Spasmodic Dysmenorrhoea in Late Adolescence
Keywords:Adolescents ,Primary dysmenorrhoea,Harmonal contraceptives.
Introduction: Spasmodic dysmenorrhoea (SD) is defined as painful menses. Dysmenorrhoea may limit the day-to-day activities of a person. Its occurrence is 63% and it is severe in 15% of the people. It requires counselling and treatment.
Aims and Objectives: To know the efficacy of ethinyl estradiol and dienogest versus ethinyl estradiol and levonorgestrel in reducing pain among women with primary dysmenorrhoea
Methodology: This was a prospective observational study done for six months among 100 females having dysmenorrhoea. They were divided into Group A (N = 50) and Group B (N = 50). The participants of Group A received ethinyl estradiol 0.03 mg/ dienogest 2 mg and those of Group B received ethinyl estradiol 0.03 mg/ levonorgestrel 0.15 mg for three consecutive menstrual cycles. After consent from the participants, their menstrual history was noted and examinations and investigations were done. Drugs were given and follow-up was done. Side effects of these drugs seen in the subjects were noted. The collected data were analysed.
Results: Most of the subjects belonged to the age group of 15-18 years in Groups A and B (80% and 84% respectively). Severe pain was more in Group A (24%) than in Group B (16%). Absence from school was 54% versus 48% in Groups A and B respectively. Menstrual irregularities were present in 42% of subjects in Group A versus 36% in Group B. Additional symptoms were present in 12% and 8% of participants in Groups A and B respectively. Anxiety was observed among 8% and 6% of adolescents in Groups A and B respectively due to pain and menstrual irregularities. Severe pain relief was observed in 100% of participants in Group A and 96% in Group B.
Conclusion: SD is common in adolescents. It reduces the quality of life of women and should be treated. It was seen in this study that dienogest is a better option for its treatment due to a significant reduction of dysmenorrhoea with minimal side effects.
How to cite this article:
Vijayasree M, Choudary GM. A Comparative Study of Ethinyl Estradiol and Dienogest with Ethinyl Estradiol and Levonorgestrel in the Management of Spasmodic Dysmenorrhoea in Late Adolescence. Int J Adv Res Gynaecol Obstet. 2023;1(2):1-6.
LicenseCopyright (c) 2023 Author's
We, the undersigned, give an undertaking to the following effect with regard to our article entitled
________________________________________________________________________________” submitted for publication in (Journal title)________________________________________________ _______________________________________________________Vol.________, Year _________:-
1. The article mentioned above has not been published or submitted to or accepted for publication in any form, in any other journal.
2. We also vouchsafe that the authorship of this article will not be contested by anyone whose name(s) is/are not listed by us here.
3. I/We declare that I/We contributed significantly towards the research study i.e., (a) conception, design and/or analysis and interpretation of data and to (b) drafting the article or revising it critically for important intellectual content and on (c) final approval of the version to be published.
4. I/We hereby acknowledge ADRs conflict of interest policy requirement to scrupulously avoid direct and indirect conflicts of interest and, accordingly, hereby agree to promptly inform the editor or editor's designee of any business, commercial, or other proprietary support, relationships, or interests that I/We may have which relate directly or indirectly to the subject of the work.
5. I/We also agree to the authorship of the article in the following sequence:-
Authors' Names (in sequence) Signature of Authors
1. _____________________________________ _____________________________________
2. _____________________________________ _____________________________________
3. _____________________________________ _____________________________________
4. _____________________________________ _____________________________________
5. _____________________________________ _____________________________________
6. _____________________________________ _____________________________________
7. _____________________________________ _____________________________________
8. _____________________________________ _____________________________________
(I). All the authors are required to sign independently in this form in the sequence given above. In case an author has left the institution/ country and whose whereabouts are not known, the senior author may sign on his/ her behalf taking the responsibility.
(ii). No addition/ deletion/ or any change in the sequence of the authorship will be permissible at a later stage, without valid reasons and permission of the Editor.
(iii). If the authorship is contested at any stage, the article will be either returned or will not be
processed for publication till the issue is solved.